title: Rosiglitazone influences adipose tissue distribution without deleterious impact on heart rate variability in coronary heart disease patients with type 2 diabetes.
abstract: Obesity is associated with decreased heart rate variability (HRV). Rosiglitazone, a PPARγ agonist, is generally associated with increases in body mass.
  
  
  
  To assess whether the gain in body mass and adiposity expected from rosiglitazone treatment has an influence on HRV in patients with type 2 diabetes and coronary artery disease.
  
  
  
  One hundred and twenty-five patients with type 2 diabetes and coronary artery disease aged between 40 and 75 years were studied. Anthropometric measurements: (1) body mass index (BMI), (2) waist circumference (WC), (3) abdominal computed tomography (CT) scan, and HRV (using a 24 h Holter) were measured at baseline and after 12 months of treatment. Patients were randomized to rosiglitazone or placebo regimen.
  
  
  
  In the rosiglitazone vs. placebo group, there were significant increases in body mass [3.5 (2.6;4.4); mean (95 % CI) vs. 0.2 (-0.4;0.8)] kg), BMI [1.3 (1.0;1.6) vs. 0.1 (-0.1;0.3) kg/m2], WC [2.1 (0.9;3.3) vs. 0.4 (-0.4;1.2) cm, all p ≤ 0.001] and subcutaneous adipose tissue [253 (187;319) vs. 6 (-24;36) cm3, p ≤ 0.001] without statistically significant changes in visceral adipose tissue [-22 (-91;47) vs. 57 (43;71) cm3, p = 0.546], respectively. There was no change in HRV in either group after 12 months. There were no correlations between changes in HRV variables and fat distribution.
  
  
  
  Our results suggest that changes in adiposity indices observed after 12 months of rosiglitazone therapy have no deleterious influence on HRV in patients with type 2 diabetes and coronary artery disease.
authors: Institut universitaire de cardiologie et de pneumologie de Québec, Quebec City, QC, Canada.|Faculty of pharmacy, Laval University, Quebec City, QC, Canada.
authors: Audrey
authors: A
authors: Grenier
authors: Institut universitaire de cardiologie et de pneumologie de Québec, Quebec City, QC, Canada.|Department of Kinesiology, Faculty of Medicine, Laval University, Quebec City, QC, Canada.
authors: Patrice
authors: P
authors: Brassard
authors: Institut universitaire de cardiologie et de pneumologie de Québec, Quebec City, QC, Canada.
authors: Olivier F
authors: OF
authors: Bertrand
authors: Institut universitaire de cardiologie et de pneumologie de Québec, Quebec City, QC, Canada.|Department of Kinesiology, Faculty of Medicine, Laval University, Quebec City, QC, Canada.
authors: Jean-Pierre
authors: JP
authors: Després
authors: Institut universitaire de cardiologie et de pneumologie de Québec, Quebec City, QC, Canada.
authors: Olivier
authors: O
authors: Costerousse
authors: Institut universitaire de cardiologie et de pneumologie de Québec, Quebec City, QC, Canada.
authors: Natalie
authors: N
authors: Alméras
authors: Institut universitaire de cardiologie et de pneumologie de Québec, Quebec City, QC, Canada. paul.poirier@criucpq.ulaval.ca.|Faculty of pharmacy, Laval University, Quebec City, QC, Canada. paul.poirier@criucpq.ulaval.ca.
authors: Et Paul
authors: EP
authors: Poirier
mesh_terms: D050154:Adiposity / Q000187:drug effects*; D000328:Adult; D000368:Aged; D015992:Body Mass Index; D003327:Coronary Disease / Q000150:complications / Q000503:physiopathology*; D018592:Cross-Over Studies; D003924:Diabetes Mellitus, Type 2 / Q000150:complications / Q000503:physiopathology*; D004311:Double-Blind Method; D005260:Female; D006339:Heart Rate / Q000187:drug effects*; D006801:Humans; D007004:Hypoglycemic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D000077154:Rosiglitazone; D045162:Thiazolidinediones / Q000009:adverse effects / Q000627:therapeutic use*; D014057:Tomography, X-Ray Computed; D055105:Waist Circumference
chemical_list: D007004:Hypoglycemic Agents; D045162:Thiazolidinediones; D000077154:Rosiglitazone
keywords: Autonomic nervous system; Body fat distribution; Heart rate; Subcutaneous fat; Thiazolidinediones